Antibiotics in pediatric inflammatory bowel diseases: a systematic review.

Abstract

Introduction: Current therapies in pediatric Inflammatory Bowel Diseases (IBD) target the immune system and often fail to sustain long-term remission. There is a high need for development of alternative treatment strategies such as antibiotics in pediatric IBD.Areas covered: This study systematically assessed efficacy and safety of antibiotics in pediatric IBD. CENTRAL, EMBASE, and Medline were searched for Randomized Controlled Trials (RCTs). Quality assessment was conducted with the Cochrane risk-of-bias tool.Expert opinion: Two RCTs (n = 101, 4.4-18 years, 43% male) were included. Both studies had overall low risk of bias. In mild-to-moderate Crohn's disease, azithromycin+metronidazole (AZ+MET) (n = 35) compared to metronidazole (MET) alone (n = 38) did not induce a significantly different response (PCDAI drop ≥12.5 or remission) (p = 0.07). For induction of remission (PCDAI≤10), AZ+MET was more effective than MET (p = 0.025). In Acute Severe Colitis, mean 5-day-PUCAI was significantly lower in the antibiotic (vancomycin, amoxicillin, metronidazole, doxycycline)+intravenous-corticosteroids group (AB+IVCS) (n = 16) compared to IVCS alone (n=12) (p = 0.037), whereas remission (PUCAI<10) did not differ (p = 0.61). No significant drug-related adverse events were reported. Results of this systematic review of antibiotic use highlight the lack of evidence in pediatric IBD. More evidence is needed before widespread implementation in daily practice.

• Authors: Charlotte M Verburgt, W Pepijn Heutink, Lot I M Kuilboer, Julie D Dickmann, Faridi S van Etten-Jamaludin, Marc A Benninga, Wouter J de Jonge, Johan E Van Limbergen, Merit M Tabbers
• Journal: Expert review of gastroenterology & hepatology (Expert Rev Gastroenterol Hepatol) Vol. 15 Issue 8 Pg. 891-908 (Aug 2021) ISSN: 1747-4132 [Electronic] England
• PMID: 34148466 (Publication Type: Journal Article, Systematic Review)

Chemical References

• Anti-Bacterial Agents

Topics

• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Child
• Gastrointestinal Microbiome (drug effects)
• Humans
• Inflammatory Bowel Diseases (drug therapy, microbiology, physiopathology)
• Randomized Controlled Trials as Topic
• Remission Induction